We have previously shown that the surface ab T cell antigen receptor (TCR)ÁCD3 complex borne by human CD4
Introduction
ab T lymphocytes recognize peptide-MHC ligands by means of a multimeric protein ensemble termed the ab T cell antigen receptor (TCR)ÁCD3 complex. This structure is composed of a variable ab TCR dimer which binds antigens and three invariant dimers (CD3ce, de and ff) which are involved in TCRÁCD3 surface transport, stabilization and signal transduction (1) . The minimal stoichiometry, therefore, is believed to be abcedef 2 , although larger clusters of this basic monovalent TCRÁCD3 unit have been observed in certain conditions (2) . The ratio of monovalent to multivalent TCRÁCD3 varies between different T cell clones and lines, even when the receptors have the same specificity (3).
Mature CD4
+ and CD8 + ab T cells differ sharply in their MHC ligands, but their TCRÁCD3 complex is believed to be qualitatively identical. The fact that most TCRÁCD3-specific mAb bind to CD4 + ab T cells better than to CD8 + ab T cells was thus taken as evidence of quantitative differences in the number of TCRÁCD3 complexes on the surface of each cell type (4) . Unexpectedly, abTCRÁCD3 expression was shown to be more impaired in CD8
+ than in CD4 + cells when CD3c (5, 6) or CD3d (7) was absent. These observations were followed by the description of conformational and biochemical differences in the TCRÁCD3 complex between CD8
+ and CD4 + CD3c-deficient (c More recently, we reported that a CD3-specific mAb termed RW28C8 bound normal human CD8 + ab T lymphocytes better than CD4
+ ab T cells (9) . Collectively, these results are not consistent with the quantitative interpretation but, rather, with the existence of constitutive differences (i.e. qualitative) in antibody binding to the surface abTCRÁCD3 complexes borne by CD4 + versus CD8 + T cells. These differences could be due to the existence of T cell lineage-associated differences in the way the abTCRÁCD3 complex is assembled, glycosylated, trimmed or topologically pre-clustered at the cell surface.
In the present study, we have extended our observations to other mammalian species. Additionally, we have addressed the hypothesis of differential glycosylation of human CD4
+ and CD8 + cells by studying surface lectin binding and competition with CD3-specific mAb. Lastly, we have shown that the TCRÁCD3 complexes from both CD4
+ and CD8
+ cells co-exist in monovalent and multivalent complexes and the ratio between them appears to be similar. This excludes that different degrees of pre-clustering were the cause for differential antibody accessibility.
Methods

Cells
Human venous blood was obtained with informed consent from healthy donors (20 to 34 years old). Venous blood from non-human primates was obtained from anesthetized healthy adult animals belonging to Cercopithecidae (Papio sp. or baboon, Macaca sylvanus or barbary macaque and Mandrillus sphinx or mandrill), Hominidae (Gorilla gorilla and Pan troglodytes or chimpanzee), Hylobatidae (Hylobates lar or gibbon) and Lemuridae (Eulemur fulvus mayottensis or brown lemur) families. Heparinized blood or lymphoid tissue cells were obtained from 4-to 12-week-old wild-type (c + ) or CD3c-deficient (c À ) C57BL/6 euthanized mice (6) . The organs were placed in complete RPMI 1640 cell culture medium (Gibco Invitrogen; Paisley, Scotland, UK), washed and macerated through a 70-lm cell strainer to remove aggregates. To remove adherent cells, thymocytes were incubated in plastic flasks with RPMI 1640 + 10% FCS for 30 min at 37°C. Splenocytes were re-suspended in 2 ml 0.83% w/v NH 4 Cl to lyse erythrocytes.
PBMCs were isolated and in some cases activated for 12-18 h with 5 lg ml À1 PHA as described (10) . Constitutively activated Herpesvirus saimiri-transformed human T cells were obtained and grown as described (11) . This study was approved by the Institutional Review Board of Complutense University.
Antibodies
The following unconjugated mAbs were used for human and, where indicated, non-human primate samples (clone names in parentheses): anti-CD3ec/ed (UCHT1 and IOT3b) from Coulter Immunotech, Marseille, France; anti-CD3e (X35) from D. Bourel, C.R. de Transfusion Sanguine, Rennes, France; anti-CD3e (2Ad2 and RW28C8) from E. L. Reinherz, Dana-Farber Cancer Institute, Boston, MA, USA; anti-CD3e (SPV.T3b) from J. E. de Vries, The Netherlands Cancer Institute, Amsterdam, The Netherlands; anti-CD3 (F101.01) and anti-CD3ec/ed (OKT3) from Bent Rubin, CHU de Purpan, Toulouse, France; anti-CD3e (Cris7) from R. Vilella, Hospital Clínico, Barcelona, Spain; anti-CD3 (WT31), anti-TCRab (BMA031), anti-CD43 (1G10) and anti-CD3e (SP34) from BD Pharmingen (San Diego, CA, USA); anti-CD3ec/ed (Leu4/ SK7) and anti-TCRCb1 (JOVI1) from B. For non-human primate samples, the following conjugated mAbs were used (clone names in parentheses): anti-CD4FITC (M-T477) and anti-CD8aPECy5 (RPA-T8) from BD Pharmingen. The Rhesus (Macaca mulatta)-specific anti-CD3 mAb FN18 was kindly donated by D. Neville (Laboratory of Molecular Biology, National Institute of Health, Bethesda, MD, USA).
The following mAbs were used for mouse samples (clone names in parentheses): anti-CD4PE or FITC (L3T4), anti-CD8PE or FITC (Ly2), anti-TCRbFITC (H57-597), anti-CD3e-biotin (145-2C11), anti-CD3e purified from hamster (500A2), anti-LFA-1PE (CD11a), anti-CD3PE (17A2) and a hamster or rat IgG isotype control from Pharmingen (San Diego, CA, USA); anti-CD3 purified from rat (KT3) was purchased from Serotec (Oxford, UK), anti-intracellular CD3e (iCD3e, APA1/ 1) and CD3d (iCD3d, APA1/2) were obtained from B. Alarcon (CBMSO, CSIC, Universidad Autó noma, Cantoblanco, Madrid, Spain). The secondary reagents (goat anti-hamster FITC, goat anti-rat FITC and streptavidin-FITC) were also from Pharmingen.
Lectins
Several lectins were used to detect leucocyte cell surface glycans. Biotinylated peanut agglutinin from Arachis hypogaea (PNA), FITC-labeled Sambucus nigra (SNA, Vector Laboratories, Burlingame, CA, USA) bark lectin, and FITClabeled Griffonia simplicifolia lectin I (IB4, used as a negative control) from Vector Laboratories; FITC-labeled wheat germ lectin Triticum vulgaris (WGA) and FITC-labeled red kidney bean Phaseolus vulgaris (PHA-L) from Sigma (St Louis, MO, USA); Alexa fluor 488-labeled soybean agglutinin Glycine max (SBA) from Molecular Probes (Eugene, OR, USA). Recombinant human FITC-labeled galectins (Gals) Gal-1, -4, -7 glutathione-S-transferase (GST) and -8GST were prepared as described (12) (13) (14) (15) (16) For N-glycosylation inhibition, Jurkat T cells were incubated for up to 3 days with 5 lM swainsonine (Sigma) and monitored for deglycosylation using PHA-FITC or stained with anti-TCRÁCD3 mAb.
Flow cytometry
Electronic gates were used to identify CD4 + and CD8 bright lymphocytes, which are >99% abTCRÁCD3 + (as measured with BMA031) and <0.2% cdTCRÁCD3 + (as measured with 11F2 or Inmuno510, data not shown). Human abTCRÁCD3-associated epitopes within CD4 + or CD8 bright subsets were analyzed by three-color flow cytometry on PBMC as described elsewhere (11) . Briefly, 5 3 10 5 cells were stained with CD3-or TCR-specific mAb (30 min, 4°C), washed twice in PBS-BSA and incubated for 20 min at 4°C with antimouse IgG-PE, followed by two washes in PBS-BSA and a subsequent incubation for 20 min at 4°C with anti-CD4FITC and anti-CD8PECy5. For comparative stainings, the mean fluorescence intensity (MFI) was used. Samples were analyzed as above.
For other primates, whole blood samples were analyzed. Briefly, 100 ll of thoroughly mixed blood was incubated for 15 min at 4°C in 12 3 75 mm polypropylene tubes, with CD3-or TCR-specific mAb, and processed as above. After incubation, 2.5 ml of lysis solution (0.15 M NH 4 Cl, 0.1 mM KHCO 3 , 0.1 mM EDTA) was added, the tubes were incubated for 10 min at room temperature (22 6 3°C) in the dark and centrifuged for 10 min at 4°C per 200 g. The cell pellets were resuspended in 500 ll of PBS-BSA before analysis as above.
For mouse samples, 0.5-1 3 10 6 cells were washed and re-suspended in PBS-BSA with 20 lg ml À1 mouse IgG, incubated for 20 min at 4°C and washed twice with PBS-BSA. Two-color stainings were performed with purified hamster anti-mouse mAb followed by anti-hamster Ig-FITC (20 min, 4°C) and two washes with PBS-BSA before anti-CD4PE or anti-CD8PE stainings. Control stainings with secondary antibody only were performed routinely. Twenty thousand events from each sample were analyzed in a FACScan using the CellQuest software (Becton Dickinson, San Jose, CA, USA). Intracellular stainings were performed as described previously (17) . Briefly, lymph node cells from 6-week-old C57BL/6 mice were directly stained with PE-labeled anti-CD4 or anti-CD8 and fixed and permeabilized using the Cytofix/Cytoperm kit (Pharmingen). Cells were then incubated with 4 lg ml À1 biotin-labeled APA1/1 or APA1/2 for 30 min on ice, stained with streptavidin-FITC and analyzed by flow cytometry in a FACSCalibur.
Membrane preparation, blue native-PAGE and immunoblotting
The 5 3 10 6 sorted CD4 + and CD8 + lymphocytes or Jurkat T cells were allowed to swell for 10 min in 1 ml hypotonic buffer (10 mM HEPES, pH 7.4, 42 mM KCl, 5 mM MgCl 2 and protease inhibitors). The cells were then disrupted using a Dounce homogenizer and the membranes were pelleted in an ultracentrifuge TLA 100 (Beckman Instruments, Gagny, France) at 48 000 r.p.m. for 30 min. Membranes were lysed in 25 ll blue native (BN) buffer (500 mM 6-aminohexanoic acid, 20 mM NaCl, 10% glycerol, 2 mM EDTA, 20 mM bisTris, pH 7 and protease inhibitors) containing the appropriate detergent (0.3% Brij96 or 0.5% digitonin). The clarified membrane lysates were separated by BN-PAGE (4-9%) as described (3) . Semi-dry transfer of the proteins to a polyvinylidene difluoride membrane was done. Immunoblots were developed with an anti-f antiserum. Ferritins in its 24mer (f1; 440 kD) and 48mer (f2; 880 kD) forms were included as molecular mass standards.
Results
Differential antibody binding to the abTCRÁCD3 complex of primary CD4 + and CD8 + T lymphocytes is phylogenetically conserved
We reported previously that the abTCRÁCD3 complex borne by human primary CD4 + and CD8 + T lymphocytes is not identical because certain mAbs, such as SP34 or UCHT1, bind the former better, whereas other mAb, such as RW28C8, bind the latter better (9) . In order to extend these observations to other species, we studied six non-human primates and mice. The results are summarized in Fig. 1 in comparison to humans. First, not all human-specific CD3 mAb bound non-human primate T cells, but those which did (denoted by + and +/À under the graph in Fig. 1B ) confirmed the findings above ( Fig. 1A and B) . Interestingly, in some cases CD4
+ , but not CD8 + , T cells were bound very poorly by RW28C8 (Mandrill, for instance, Fig. 1A ). Second, mouse T cells were scanned using an entirely different set of mAb ( Fig. 1A-C) . The result indicated that the mouse surface abTCRÁCD3 complex from CD4 + T cells, as shown for primates, was bound better than that of CD8 + T cells by most (2C11, 17A2, 500A2), but not all (KT3) CD3-specific mAb. This was most likely due to extracellular differences, since differential binding was not apparent upon staining intracellular CD3 epitopes, such as those recognized by APA1/1 (iCD3e) or APA1/2 (iCD3d, Fig. 1B and C) . Thus, KT3 in mice mimics RW28C8, as it bound better to CD8 + than to CD4 + cells. This indicates that the antibody-binding
Conserved lineage-associated variation in abTCRÁCD3 1249 + relative to CD8 + peripheral blood T cells with the indicated mAb in n independent individuals. For non-human primates, the (similar) results of different species were pooled to simplify the figure. '+' means clear binding of the indicated CD3 mAb to CD4 + or CD8 + T cells as shown in (A) for Mandrill; 'À' and '+/À' stand for no or weak binding to both T cell subsets, respectively; ND, not done; eCD3, extracellular CD3. MFI ratios were calculated only for + and +/À samples. Brown lemur T cells were omitted, as they did not show specific binding to the mAbs assayed. MFI ratios above or below 1 (indicated by the horizontal dotted line) reflect an increased or decreased mAb binding to CD4 + cells, respectively. Statistical significance (Student's t-test) is shown only for selected mAb. As invariant controls, CD18, CD5, CD43 or CD11a were evaluated, together with intracellular CD3 (iCD3; APA1/1 and APA1/2) in mouse samples (C) MFI ratios as in panel differences to the surface abTCRÁCD3 complex of CD4 + and CD8
+ T lymphocytes are conserved in evolution. The results were confirmed in all tested mouse lymphoid tissues, including early (thymus) and late (blood, lymph node, spleen) T cell differentiation stages and also in the absence of CD3c (Fig. 1C) as reported in c À humans (9) . The observed differences in KT3 binding between CD3c + and c À samples suggest that the KT3 epitope is more CD3c dependent than other mAb, such as 17A2 or 2C11. From these experiments, we conclude that the antibody-binding differences observed in humans between the surface abTCRÁCD3 complex of primary CD4
+ and CD8 + T cells are conserved in phylogeny, as well as along mouse T cell differentiation.
Activation-independent differential binding of RW28C8 to human CD4 + and CD8 + T-lineage lymphocytes
Antigen recognition causes profound surface changes in T lymphocytes (18) and in the TCRÁCD3 complex (19) .
To determine whether the observed abTCRÁCD3 antibodybinding differences were regulated by activation, we compared antibody reactivities in human CD4 + and CD8 + T lymphocytes, either resting or recently activated (shortterm CD69 + PBMC blasts) or constitutively activated by H. saimiri transformation (20) . Activation had an impact on abTCRÁCD3 antibody binding as measured with UCHT1, but the changes did not affect recognition of the RW28C8 epitope, which remained more strongly expressed by CD8 + T lymphocytes even after H. saimiri transformation (Fig. 1D) . Specific interference by the CD4 molecule is unlikely, as binding of RW28C8 was enhanced even further in human CD4 +
CD8
+ immature T cells (9) .
To further characterize RW28C8 binding to human CD4 + versus CD8 + T lymphocytes, we performed comparative titrations (21) using UCHT1 and CD18 as controls. The results showed that, in contrast to both control mAb, which were diluted out with similar slopes from CD4 + and CD8 + T cells, RW28C8 binding dropped more rapidly from CD8 + than from CD4 + T cells (Fig. 2) . Therefore, while the epitopes recognized by UCHT1 may be quantitatively more common on CD4
+ than on CD8 + T cells (or similar in numbers in the case of CD18), but qualitatively identical, RW28C8 binds to an activation-independent epitope which is different between CD4
+ and CD8 + T-lineage cells.
Differential cell surface glycosylation of human primary CD4 + and CD8 + T lymphocytes
The observed lineage-associated abTCRÁCD3 antibodybinding differences could be caused by developmentally acquired features that distinguish the two cell types, including their glycosylation machinery (22, 23) . Lectins are carbohydrate-binding proteins derived from plants and animals that can be used for identification, purification and characterization of glycoconjugates (24) . Human primary lymphocytes, both resting and activated, were incubated with a large panel of lectins. For the glycan recognition patterns of some of them, see Fig. 3(C) . Three of five tested plant lectins and one of five tested human Gals bound resting human primary lymphocytes strongly (Fig. 3A , where binding to monocytes was used as a positive control). The four lymphocyte-binding lectins were next analyzed comparatively within CD4 + and CD8 + T cells ( Fig. 3B and D) . All four lectins, but particularly Gal-7 (P < 0.05 versus the other three), bound resting CD8 
T cells better than resting CD4
+ T cells, supporting the existence of differential glycosylation between them. Differential Gal-7 binding was dependent on carbohydrate recognition, since it was completely blocked by lactose in both cells types (Fig. 3E) .
T cell activation has a profound impact on the patterns of cell surface glycosylation (25) . Accordingly, activation increased lectin binding to lymphocytes (Fig. 3D ), but again differentially on each cell subset. In general, lectin binding was increased to a higher extent on CD4
+ cells than on CD8 + T cells following activation, and this was particularly evident in the case of Gal-7 binding (Fig. 3B and D) .
Taken together, these results are compatible with the existence of differential cell surface glycosylation patterns between human primary CD4 + and CD8 + T lymphocytes, which can be modified upon activation. Differential lectin competition with CD3 mAb binding to human primary CD4 + and CD8 + T lymphocytes
To establish if the observed lineage-associated cell surface glycosylation differences were involved in the generation of distinct abTCRÁCD3 configurations in CD4 + and CD8 + T cells, human PBMCs were incubated with increasing amounts of the four lymphocyte-binding lectins before staining with four representative CD3-specific mAb and analyzed within CD4 + and CD8 + T lymphocytes. The results are summarized in Fig. 4 and Table 1 . The CD4-and CD8-specific mAbs were unaffected by most lectins (Fig. 4A and B , and data not shown), with the exception of WGA which competed with anti-CD4 binding (data not shown), and it was thus excluded from the analysis. Among the remaining 12 lectin/CD3 mAb combinations, all possible competition results were observed (Fig. 4A and C) . In some cases, the lectin did not hinder binding of certain CD3 mAb (Gal-7/ RW28C8, Fig. 4A, right) . Thus, neither the percentage of CD3 + , CD4
+ or CD8 + T lymphocytes (Fig. 4A , top right) nor CD3 MFI within CD4 + or CD8 + T cells (Fig. 4A , bottom right) was affected by the lectin. In other cases (Leu4), the percentage of CD3 + cells was reduced to different extents in a lectin dose-dependent fashion (Fig. 4A, top) , with SNA > PHA-L > Gal-7, as reflected by the indicated slopes. Among these cases, three different situations were observed (as reflected by the slopes shown in Fig. 4A, 
bottom): (i) CD3 binding was reduced similarly in CD4
+ and CD8 + T lymphocytes (SNA/Leu4, representative histograms in Fig. 4B ), (ii) CD3 binding was more reduced in CD8
+ than in CD4 + T lymphocytes (Gal-7/Leu4) and (iii) CD3 binding was more reduced in CD4
+ than in CD8 + T lymphocytes (PHA-L/Leu4, representative histograms in Fig. 4B) .
From these experiments, we conclude that lectin binding to human primary CD4 + and CD8 + T lymphocytes differentially competes with CD3 mAb recognition of these subsets, thus suggesting that differential glycosylation may be responsible for the observed lineage-associated abTCRÁCD3 antibody-binding differences.
In order to prove directly that glycosylation hinders antibody binding to the abTCRÁCD3, we incubated Jurkat T cells with swainsonine, an early inhibitor of N-glycosylation, and stained the cells with abTCRÁCD3-specific mAb (BMA031, RW8C8 and OKT3). PHA-FITC binding was used as a probe for impaired N-glycosylation. The results indicated that, in sharp contrast with PHA, all tested mAbs, particularly BMA031, bound better the abTCRÁCD3 after swainsonine treatment (Fig. 4D) . This indicates that the mAb-binding sites were covered in part by N-glycans.
Native analysis of the multivalent TCRÁCD3 complexes on CD4 + and CD8 + lymphocytes
The differential binding of anti-CD3 mAbs to CD4 + versus CD8 + T cells could also be explained if the ratio of monovalent to multivalent TCRÁCD3 varied between these cell types.
To address this, we performed BN PAGE analysis of total membrane fractions from both cell types (Fig. 5) . As seen previously (9) , the TCRÁCD3 complex extracted by the detergent digitonin is similar in size in both CD4
+ and CD8 + T cells. Since digitonin disrupts the multivalent complexes, only the monovalent ones with the abcedef 2 stoichiometry remain (2) . Here, additionally, we also extracted the TCRÁCD3 from membrane fractions using the detergent Brij96. This detergent keeps both multivalent and monovalent TCRÁCD3 complexes intact (2) . The monovalent complex extracted with Brij96 appears as a broader band than the one seen with digitonin as reported (2) . This was probably due to different detergent micelles. The large molecular weight complexes are the multivalent TCRÁCD3s. Previously, we have shown that these large complexes are not an artifact due to insufficient membrane solubilization or aggregation during the electrophoresis (2). Indeed, they correspond to the multivalent complexes detected by electron microscopy (2) and fluorescence resonance energy transfer measurements (26) on intact cells. The amount of multivalent TCRÁCD3 present on CD4 + cells is similar to that seen in CD8 + cells (Fig. 5) . This is comparable to the amount of multimers seen in the human T cell line Jurkat. In conclusion, the ratio of monovalent to multivalent TCRÁCD3 was the same in CD4
+ and CD8 + peripheral T cells, thus ruling it out as the cause of differential antibody binding.
Discussion
Phylogenetically conserved differences between the surface abTCRÁCD3 complex of primary CD4 + and CD8
+ T lymphocytes
We have used two unrelated sets of TCRÁCD3-specific mAb to probe comparatively the surface abTCRÁCD3 complex of primary CD4
+ and CD8 + T lymphocytes from seven different mammalian species. Our results demonstrate that the TCRÁCD3 antibody-binding differences reported initially for human CD4
+ and CD8 + T cells (8, 9) are conserved in mammal evolution and thus of potential adaptive value. Therefore, CD8
+ T cells appear to be distinguished from their CD4 + counterparts not only by the expression of the specific coreceptor but also based on a distinct configuration of their surface abTCRÁCD3 complexes, which is phylogenetically conserved and independent from T cell receptor specificity and activation status.
Differential glycosylation of human T cell subsets and of their surface abTCRÁCD3 complex
Our lectin binding results indicate that the surface of human CD4 + and CD8 + T cells is differentially decorated by lectin ligands as proposed in Fig. 6 . Indeed, 4 of the 12 tested lectins, particularly Gal-7, bound to CD8 + better than to CD4 + resting T cells (Fig. 3B and C) . Differential effects of glycosylation on specific T cell lineages have been reported previously. For instance, sialyltransferase ST3 Gal-I deficient mice lacked CD8 + , but not CD4 + , T lymphocytes (27) . Conversely, mice lacking the heavily glycosylated CD83 receptor showed impaired CD4
+ , but not CD8 + , T cell development (28). More recently, primary mouse CD4 + and CD8 + T cells have been shown to have different profiles of N-linked glycans (25) .
As the abTCRÁCD3 is a complex ensemble of surface glycoproteins, it is likely affected by the general differences in the pattern of glycosylation between CD4 + and CD8 + T cells.
Conserved lineage-associated variation in abTCRÁCD3 1253
Several pieces of evidence provide support for this contention. First, we have shown that there is differential lectin competition with CD3 mAb binding to human primary CD4 + and CD8 + T cells (Fig. 4 and Table 1 ). Second, our immunoprecipitation experiments revealed clear biochemical differences associated to TCR (but not CD3) chains between native, but not N-glycosydase-treated, CD8
+ and CD4 + T cell samples (9) . These differences extend to the CD3d subunit in T cells from CD3c-deficient humans (8) . Third, surface desialylation by treatment with N-acetyl neuraminidase increased RW28C8 binding to both CD4
+ and CD8 + T cells, but more prominently in the former, so that the gross binding of the antibody was then similar in both T cell lineages (9) . Thus, the epitope recognized by RW28C8 appeared to be masked by sialic acid residues, particularly in CD4 + T cells ( Fig. 4D and 6 ). This is reminiscent of the binding of the anti-CD3 antibody WT31 to cd T cells, where the originally poor binding is markedly improved upon neuraminidase treatment (see below). Fourth, antibodies against intracellular CD3e or CD3d epitopes bind CD4 + and CD8 + T cells similarly ( Fig. 1B and C) . We believe that TCR rather than CD3 glycosylation is responsible for the antibody-binding differences (Fig. 6) . Briefly, the human abTCRÁCD3 has four potential N-glycosylation sites on TCRa and two each on TCRb, CD3c and CD3d, whereas the mouse abTCRÁCD3 has 3, 4, 1 and 3, respectively. However, recent structural data (29) revealed an oblique, side-on nature of OKT3 binding to the top of human CD3e, in a region dominated by a linear stretch of sequence on the F-G loop. Thus, it appears rather unlikely that glycans on CD3d or CD3c, which in fact point away from the dimer interface, could interfere with the binding of OKT3 or other overlapping anti-CD3 mAb, i.e. UCHT1. In fact, UCHT1 can immunoprecipitate both TCRÁCD3ed and TCRÁCD3ec hemicomplexes (30) , indicating that its epitope is probably exposed on both CD3e chains in a complete abTCRÁCD3 ensemble and that UCHT1 binding is not affected by the sugars associated to CD3c or CD3d. Further, eliminating individually the N-glycosylation sites of human CD3c (31) did not affect the binding of UCHT1 to the surface abTCRÁCD3 complex. Yet, simultaneously ) for CD3 mAb binding (% positive cells and MFI) after lectin pre-incubation as depicted in Fig. 4(A) . Slopes closer to 0 reflect weak or no competition of lectins with mAb. Lower negative slopes reflect strong competition with mAb. Slopes with strong linear correlation (r < À0.84, r 2 > 0.7) are highlighted in bold face. See Fig. 4 (B) for a summary of results and Fig. 4 (A and C) for representative results and experiments.
disrupting the two sites decreased UCHT1 binding, but in this case, as a result of impaired abTCRÁCD3 structural stability and surface expression.
That glycosylation influences the binding of CD3-specific mAb is not without precedent. WT31, which binds much better ab than cd TCRÁCD3, strongly binds the latter after desialylation (32) . Activation of mouse cd T cells results in differential glycosylation of the CD3c subunit which correlated with impaired binding of the anti-CD3c mAb H25 (19) . Lastly, Mgat5 À/À mouse T lymphocytes lacking Mgat5 Nglycan products, and thus PHA ligands, are bound better by the anti-CD3 mAb 2C11 (33) , suggesting that N-glycans in part hide 2C11-binding sites. Similarly, we have shown that swainsonine-treated human T lymphocytes partially lacking N-glycan products, and thus PHA ligands, were bound better by several anti-TCRÁCD3 mAb (Fig. 4D) , again suggesting that N-glycans in part hide their binding sites, as proposed in Fig. 6 . The buried surface area at the OKT3/ CD3ec interface is atypically small (29) , which may reflect the small target exposed by CD3e within the TCRÁCD3 complex. This structural feature could explain the finding that many anti-CD3 mAb recognize the same epitope as OKT3 (or an overlapping one). It would also explain that small changes in the vicinity of the antibody-binding site (as those generated by differential glycosylation) could have a marked impact on antibody binding, as the one we described here that differentiates CD4
+ from CD8 + T cells. A thorough comparative analysis of N-and O-glycan content and glycosyltransferase and glycosidases in CD4 + and CD8 + T cells is thus warranted. One such study has shown recently discordant expression of several glycosyl transferases between the two main T cell lineages in mice (25) .
Clinical and diagnostic implications
The TCRÁCD3 antibody-binding differences could be of relevance to T cell pathophysiology and may be exploited in the clinical setting. For instance, antibodies such as RW28C8 which bind with more avidity CD8 + than CD4 + T cells (Fig. 1 ) could be useful to modulate the numbers and/or function of CD8 + T lymphocytes in transplantation and autoimmunity (34, 35) . Disruption of N-glycosylation by Mgat5 ablation has been shown to lower T lymphocyte activation thresholds and cause autoimmunity (33) . Similarly, the differential glycosylation of CD4 + versus CD8 + T cells could cause differential activation thresholds and/or mechanisms. Indeed, it has been shown recently that TCRÁCD3 and CD4 are kept outside lipid rafts by a molecular Gal/N-glycan lattice that regulates activation thresholds (36) , and developmentally regulated variation in CD8 sialylation may contribute to the developmental tuning of T cell sensitivity (37) .
From the diagnostic standpoint, the results beg caution about interpretation of CD3 expression and T cell numbers when certain antibodies are used, particularly in human congenital disorders of glycosylation (38) . + and CD8 + T lymphocytes. TCR and CD3 chains (greek letters) as well as their stoichiometry would be identical in the two cell types. In contrast, the amount and diversity of glycans (in gray) may vary (most likely in TCR chains, as shown), so that certain mAb epitopes (RW28C8 filled circles, Leu4/SK7 filled squares) would be partially hidden in one or the other cell type, hindering mAb access in a CD3c-independent fashion, as shown in Fig. 1 for several mammalian species. In addition, the differential distribution of lectin binding sites (PHA-L filled triangle, Gal-7 filled pentagon) near certain mAb epitopes (Leu4/SK7 in this very simplified diagram) would account for their cell lineage-specific competition with mAb binding, as shown in Fig. 4 . + and CD8 + T lymphocytes. Membrane fractions were prepared from sorted, non-stimulated CD4 + or CD8 + human PBMCs and the human ab T cell line Jurkat. The membranes were lysed in either digitonin (lanes 1-3) or Brij96 (lanes 4-6) and separated by BN PAGE. Immunoblotting was performed with an anti-f serum to detect only fully assembled TCRÁCD3 complexes. The position of monovalent and multivalent receptors is shown to the right. The marker protein is ferritin in its 24mer (f1) and 48mer (f2) forms.
Equal ratio of mono-versus multivalent TCRÁCD3 in human CD4 + and CD8 + T cells
The size of the monovalent TCRÁCD3, as obtained by lysis in digitonin, was identical in CD4 + and CD8 + resting T cells. This demonstrates that the stoichiometry is the same in both lineages, namely abcedef 2 (2, 9, Fig. 6 ). The assembly of the TCRÁCD3 takes place in the endoplasmic reticulum before the enzymes of the Golgi apparatus confer differential glycosylation. Therefore, folding and assembly occur under similar conditions, leading to the same stoichiometry. Lastly, we show that the TCRÁCD3 of both CD4
+ and CD8 + co-exist in monovalent and multivalent complexes. Since both cell types show similar amounts of multimerized receptor complexes, we can conclude that the presence of multivalent complexes does not contribute to the differential mAb binding seen here. Earlier, we proposed that specific proteinprotein interactions are responsible for the formation of the multivalent TCRÁCD3 (2) . Since variations in glycosylation of the TCRÁCD3 do not seem to affect the ability of the complex to form multimers, the carbohydrate groups do not play a role in the generation of the multivalent TCRÁCD3.
In conclusion, we have described a phylogenetically conserved trait in the ab TCR distinguishing CD4
+ from CD8 + T lymphocytes, which is likely emerging from the distinct patterns of glycoforms decorating the surface of these T cell subsets. Yet, the contribution of other factors, i.e. lineagespecific lipid raft distribution (9) , cannot be presently ruled out. The challenge now is to understand how the distinct glycosylation status of the abTCRÁCD3 complex affects receptor signaling, gene expression and function of CD4 + and CD8 + T cells. Complex N-glycans and their degree of branching have been reported recently to regulate T lymphocyte proliferation and differentiation (39) . Therefore, lineage-specific glycosylation differences may have a major impact on CD4 + versus CD8 + T cell differentiation and function (29, 30) . The design of therapeutic strategies based on these findings deserves further investigation. 
